Core Insights - Cannara Biotech Inc. has been recognized with two awards at the 2025 Grow Up Awards Gala, including Brand of the Year for its Tribal brand and Accessory of the Year for its Nugz Happle product, highlighting its commitment to product excellence and innovation in the Canadian cannabis industry [1][2][3] Financial Management - The company has made a $1 million repayment against its Olymbec convertible debenture, which was originally issued on June 21, 2021, reflecting a disciplined approach to capital management and a commitment to reducing leverage while maintaining financial flexibility [4] - Cannara has achieved a total reduction of 50 basis points in the interest rate spread on its BMO Credit Facility, resulting in an overall cost of debt now below 6%, underscoring its strong financial performance and disciplined capital structure management [6] Industry Recognition - The Grow Up Conference and Expo is recognized as one of Canada's leading industry events, with the Grow Up Awards being one of the industry's highest honors, selected through open voting by industry participants and the public [3]

Group 1 - Herbal Dispatch Inc. announced the successful passing of all resolutions at its 2024 and 2025 Annual General and Special Meetings of Shareholders held on June 17, 2025 [1][2] - Shareholders voted to set the number of directors at 3, electing Philip Campbell, Drew Malcolm, and Herb Dhaliwal as directors [2] - Kingston Ross Pasnak LLP was appointed as the Company's auditor for the upcoming year, and the Amended & Restated Stock Option Plan and Restricted Share Unit Plan were approved [2] Group 2 - The Company sought dis-interested shareholder approval for two ordinary resolutions regarding amendments to Unsecured Convertible Debentures [3][4] - The first resolution ratified the third amendment to the 0971289 Unsecured Convertible Debenture, excluding votes from certain related parties, and received majority approval [4] - The second resolution ratified the first amendment to the Herb Dhaliwal Unsecured Convertible Debenture, also excluding votes from related parties, and obtained majority approval [4][5] Group 3 - The amendments to the Unsecured Convertible Debentures are classified as "related party transactions" under Multilateral Instrument 61-101, and the Company is relying on exemptions from formal valuation requirements [5] - The Company did not file a material change report more than 21 days prior to the effective date of these transactions, as they required ratification by dis-interested shareholder approval [6] Group 4 - Herbal Dispatch Inc. operates leading cannabis e-commerce platforms, focusing on providing high-quality cannabis products at affordable prices [7] - The flagship marketplace, herbaldispatch.com, offers exclusive access to small-batch craft cannabis flower and a variety of other product formats [7]

Core Points - MediPharm Labs Corp. held its annual and special meeting where key resolutions were voted on by shareholders [1][2] - A total of 210,726,733 common shares were represented, accounting for 50.76% of the total issued shares [2] - The meeting resulted in the approval of several resolutions including the number of directors, appointment of auditors, election of directors, and unallocated awards under the equity incentive plan [3] Voting Results - The resolution to fix the number of directors at seven was approved with 75.46% voting in favor [5] - All management director nominees were elected with Chris Halyk receiving 144,007,422 votes and Emily Jameson receiving 144,289,930 votes [6] - MNP LLP was appointed as the auditor with 90.78% of votes in favor [7] - The resolution for unallocated awards under the equity incentive plan was narrowly approved with 50.14% voting for and 49.86% against [8] Board Changes - New directors Emily Jameson and John Medland were welcomed to the Board, while Michael Bumby did not stand for re-election [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products [9] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [10] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [11]

Core Insights - Vireo Growth Inc. has completed a series of merger agreements, positioning itself as one of the largest multi-state cannabis operators in the U.S. with operations in six states [1] - The company anticipates pro forma revenue for Q2 2025 to be between $88 million and $91 million, with adjusted EBITDA expected to be in the range of $23 million to $24 million [2] - Vireo's management believes that its improved profitability will facilitate more favorable terms for refinancing its outstanding debt obligations, with expectations of a cash position exceeding $100 million post-refinancing [3] - Following the mergers, Vireo has approximately 949 million basic shares outstanding and about 1.087 billion shares on a fully-diluted basis [4] Financial Performance - Pro forma revenue for Q2 2025 is projected to be between $88 million and $91 million, while adjusted EBITDA is expected to range from $23 million to $24 million [2] - The company is currently unable to estimate net income due to uncertainties related to non-cash expenses and accounting adjustments [2] Debt Refinancing - Vireo is engaged in discussions to refinance its outstanding senior secured debt under more favorable terms, including debt from recent merger transactions [3] - The company has signed multiple non-binding term sheets and expects the refinancing event to close quickly, resulting in a cash position of over $100 million [3] Share Structure - The company has reported 949,254,483 basic shares outstanding on an as-converted basis and 1,087,283,616 shares on a fully-diluted basis following the merger transactions [4]

Core Viewpoint - Canopy Growth has significantly underperformed in the cannabis industry, losing 99% of its value over the past five years, with shares trading under $2, making it unattractive for investment [1][11]. Financial Performance - Canopy Growth reported a net revenue of 65 million Canadian dollars for Q4 of fiscal year 2025, down 11% year-over-year, despite a 4% increase in cannabis revenue in Canada [6]. - The company remains deeply unprofitable, with a net loss per share of CA$1.43, worsening from a CA$1.03 loss per share in the previous year [7]. Market Challenges - The cannabis market is heavily regulated, leading to stiff competition and oversupply issues, particularly in Canada and the U.S., where cannabis remains illegal at the federal level [4][10]. - Canopy Growth's international operations, including its subsidiary Storz & Bickel, have not mitigated the negative impact on overall performance [2][6]. Management Outlook - Management has attempted to present a positive outlook by highlighting a 49% reduction in total debt during fiscal year 2025 and aims to achieve positive adjusted EBITDA in the "near term" [8][9]. - Despite potential long-term opportunities in the U.S. cannabis market, the vague nature of management's goals raises skepticism about the company's future profitability [8][9]. Investment Sentiment - The current lack of revenue growth and the uncertain regulatory environment in the U.S. contribute to the view that Canopy Growth is not an attractive investment option [10][11].

Core Viewpoint - Red White & Bloom Brands Inc. is currently under a management cease trade order (MCTO) due to delays in filing its financial statements for the fiscal year ended December 31, 2024, and is providing updates on the status of this order [1][2]. Group 1: Management Cease Trade Order (MCTO) - The MCTO was granted on May 1, 2025, by the British Columbia Securities Commission under National Policy 12-203 [1][2]. - The company is required to issue bi-weekly default status reports while remaining in default of the Annual Filings requirement [5]. Group 2: Financial Filings Update - The audit for the Annual Filings is ongoing, with an expected update on the timing around June 23, 2025, if the filings are not completed by then [3]. - The company is also working on its interim financial statements for the first quarter ended March 31, 2025, which will be filed within five business days after the Annual Filings are completed [3]. Group 3: Trading Status - During the MCTO, the general investing public can continue to trade the company's common shares, but the company's CEO, president, and CFO are prohibited from trading [4]. Group 4: Company Overview - Red White & Bloom Brands Inc. operates as a multi-jurisdictional cannabis operator, focusing on major U.S. markets such as California, Florida, Missouri, Michigan, and Ohio, as well as Canadian and international markets [6].

Core Viewpoint - AYR Wellness Inc. has delayed the filing of its interim financial statements for the period ended March 31, 2025, primarily due to ongoing negotiations with creditors and assessment of debt obligations [1][2] Group 1: Financial Filings and Delays - The interim financial statements, management's discussion and analysis, and related CEO and CFO certificates were not filed by the anticipated date of June 13, 2025 [1] - The delay is attributed to negotiations with creditors and the evaluation of accounting classifications of certain debt obligations [2] - AYR is working to complete the interim filings as soon as possible and will provide an update on the timing by June 27, 2025 [4] Group 2: Regulatory Actions - The Ontario Securities Commission has issued a failure-to-file cease-trade order (FFCTO), prohibiting all trading in AYR's securities in Canada [3] - The FFCTO will remain in effect until AYR completes and files the interim filings and meets all Canadian Securities Exchange requirements [3] Group 3: Company Operations - Despite the FFCTO, AYR does not expect any impact on its ability to operate in the ordinary course [4] - AYR Wellness operates as a vertically integrated U.S. multi-state cannabis business with over 90 licensed dispensaries [6]

Core Viewpoint - Planet 13 Holdings Inc. held its Annual General Meeting of Stockholders on June 10, 2025, where key business items were voted on, including the election of directors, amendments to the equity incentive plan, and the appointment of auditors [1]. Group 1: Election of Directors - The election results for directors showed varying levels of support, with Larry Scheffler receiving 93.7% approval and Robert Groesbeck receiving 73.4% [2]. Group 2: Amendment to Equity Incentive Plan - An amendment to increase the number of shares authorized for issuance under the 2023 Equity Incentive Plan from 22 million to 32 million was approved with 81.5% voting in favor [3]. Group 3: Re-Appointment and Remuneration of Auditors - The appointment of Davidson & Company LLP as the independent registered public accounting firm was ratified with 91.9% approval [4]. Group 4: Company Overview - Planet 13 is a vertically integrated cannabis company with operations in California, Nevada, Illinois, and Florida, known for its large dispensary in Las Vegas and recent expansion into Illinois [5].

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to support its current strategy and board nominees while rejecting the dissident group's proposals, emphasizing the success of its recent transformation and growth strategy [1][3][5]. Company Strategy and Performance - MediPharm has successfully transformed its operations over the past three years, focusing on strategic business lines, divesting non-core assets, and reducing operating costs, which has led to improved financial performance [3][4]. - The acquisition of VIVO Cannabis Inc. in April 2023 has accelerated international growth and created synergies, contributing to the company's positive trajectory [3][15]. - In Q1 2025, MediPharm reported an 87% revenue increase in the international medical market, achieving positive Adjusted EBITDA for the first time in over five years, with a gross profit margin of 38.7% [4][5]. Shareholder Engagement - The company is encouraging shareholders to vote using the GREEN proxy to support its board nominees and resolutions, emphasizing the importance of each vote [2][11]. - MediPharm has provided resources for shareholders to ensure their votes are counted and to disregard communications from the dissident group [12][18]. Dissident Group's Position - The dissident group, led by Apollo Technology Capital Corp. and former MediPharm CEO Patrick McCutcheon, has proposed alternative directors but has been criticized for lacking a substantive plan and for misrepresentations in their communications [6][7]. - Independent advisory firm ISS has concluded that the dissident group did not present a compelling case for change, reinforcing the company's position [7]. Historical Context - The company highlights the negative performance metrics during McCutcheon's tenure, including a 72% revenue decrease in 2020 and significant operating losses, contrasting this with the current leadership's improvements since 2022 [9][16].

Core Points - Herbal Dispatch Inc. has adjourned its 2024 and 2025 Annual General and Special Shareholder Meeting originally scheduled for June 10, 2025, to June 17, 2025 [1] - The adjourned meeting will be held virtually via Zoom and physically at a specified location in Vancouver, B.C. [1] - The company was unable to meet its proxy requirements for the former meeting, necessitating the adjournment [2] - All proxies submitted for the former meeting will remain valid for the adjourned meeting unless revoked or amended [3] Company Overview - Herbal Dispatch Inc. operates leading cannabis e-commerce platforms and aims to provide high-quality cannabis products at affordable prices [6] - The company's flagship marketplace, herbaldispatch.com, offers exclusive access to small-batch craft cannabis flower and various other product formats [6] - Herbal Dispatch's common shares are traded on the Canadian Securities Exchange under the symbol "HERB" [6]